Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition

Reperfusion is essential for ischemic myocardium but paradoxically leads to myocardial damage that worsens cardiac functions. Ferroptosis often occurs in cardiomyocytes during ischemia/reperfusion (I/R). The SGLT2 inhibitor dapagliflozin (DAPA) exerts cardioprotective effects independent of hypoglyc...

Descripció completa

Dades bibliogràfiques

Autors principals:	Weixiang Chen, Yue Zhang, Zuoxiang Wang, Mingyue Tan, Jia Lin, Xiaodong Qian, Hongxia Li, Tingbo Jiang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-02-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	myocardial ischemia/reperfusion dapagliflozin ferroptosis MAPK pathway treatment
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1078205/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!